Clinical Trials Logo

Unresectable Esophageal Cancer clinical trials

View clinical trials related to Unresectable Esophageal Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT06251973 Recruiting - Clinical trials for Metastatic Gastric Cancer

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.

NCT ID: NCT04137679 Recruiting - Clinical trials for Unresectable Esophageal Cancer

Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO

Start date: November 1, 2019
Phase: Phase 2
Study type: Interventional

Definitive chemoradiotherapy(CRT) has been regarded as a standard of care for patients with unresectable locally advanced esophageal cancer. Patients who are sensitive to CRT can achieve significantly down staging. Whether this part of patients could benefit from further surgical treatment remains unknown. Herein, a single center prospective randomized phase II clinical trial will be carried out to compare efficacy and safety of definitive CRT versus neo-CRT plus radical resection in patients who achieved down staging after neo-CRT for stage T4NxM0 esophageal Cancer.

NCT ID: NCT04005170 Completed - Clinical trials for Unresectable Esophageal Cancer

Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

Start date: June 25, 2019
Phase: Phase 2
Study type: Interventional

Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. The aim of this study was to evaluate the efficacy and safety of the combination of toripalimab (an anti-PD-1 antibody) combined with definitive CRT in locally advanced esophageal squamous cell carcinoma (ESCC).